Disclosed are devices, kits, apparatus, and methods for rapid homogenous cell staining and imaging.

Methods are provided herein for determining the likelihood that a subject, such as an asymptomatic subject, has chlamydial pelvic inflammatory disease. In some embodiments, the method can determine the likelihood that a pharmaceutical agent is effective for treating a subject that has chlamydial pelvic inflammatory disease. In other specific non-limiting examples, the method predicts endometritis and elevated pathogen burden. The subject is a female, such as a human female.

The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter

Disclosed are devices, kits, apparatus, and methods for rapid homogenous cell staining and imaging.

System and method for remote self-collection of a blood sample for assessment at a lab to detect presence of specific sexually transmitted infections (STIs). An at-home collection kit may include an ability to detect chlamydia (CT), gonorrhea (GC), bacterial vaginosis (BV), candida vaginitis (CV) and Trichomonas vaginalis (TV), HSV-2, syphilis, HIV, HBsAg, an HCV. The screening of samples for the presence of antigens and/or antibodies to infectious agents is a primary laboratory tool for the diagnosis of infections of the above viruses and bacterium. Distributing a specimen collection kit containing dried blood spot (DBS) cards can eliminate the hurdles of visiting clinics or hospitals and reduce stigma. DBS samples collected on filter paper, such as GE Whatman 903 protein saver cards, offer several advantages over on-site phlebotomist collection. The DBS cards and collection devices are especially useful for individuals who live in remote areas where healthcare resources may be limited.